The ProM platform: New ways to drug the undruggablebroad
ProM · Horizon Europe grant · 2022-04-01–2025-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATOROPEN-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATOROPEN-01. CORDIS record →
Objective
Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases. To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked. PROSION developed a disruptive platform of chemical building blocks called ProMs. The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat-diseases. ProMs can be combined into small molecule drugs to target proteins that play a key-role in pathologies such as cancer, Alzheimer’s, cardiovascular diseases and immune mediated disorders.The platform’s potential is currently being validated: in its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| PROSION GMBH | DE | coordinator | €2,461,375 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.